KLK3 and pachyonychia congenita: Generally, PC is regarded as a suitable target for targeted toxin therapy, because (a) PC cells are generally slowly growing and express well described target antigens, (b) PC metastases predominantly involve lymph nodes and bones, locations that are readily accessible to circulating targeted toxins, and (c) the prostate-specific antigen (PSA) serum marker is established for the early detection of metastases and for monitoring the therapeutic efficacy.